Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

WANJIA GROUP HOLDINGS LIMITED
萬嘉集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 401)

VOLUNTARY ANNOUNCEMENT

This announcement is made by Wanjia Group Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The Company announces that Wuhua Yongke Kidney Hemodialysis Company Limited*（五華養可腎析血液透析有限公司）("**Wuhua Yongke**"), an indirect non-wholly owned subsidiary of the Company, recently received a Notice of Agreed Processing*（協議處理告知書）(the "**Notice**") dated 23 October 2025 from Wuhua County Medical Insurance Management Centre*（五華縣醫療保障事業管理中心）("**Wuhua MIMC**"). Pursuant to the Notice, due to deviation from normal medicine prescription practices in the hemodialysis treatment centre ("**Wuhua Hemodialysis Centre**") operated by Wuhua Yongke, which resulted in non-compliance under the Prescription Management Measures*（處方管理辦法), the Drug Administration Law of the People's Republic of China ("**PRC**")*（中華人民共和國藥品管理法）and the Meizhou City Designated Medical Institution Medical Insurance Service Agreement*（梅州市定點醫療機構醫療保障服務協議書）(the "**Insurance Service Agreement**"), Wuhua MIMC has accordingly subjected Wuhua Yongke to the following measures:

1. the legal representative and management of Wuhua Yongke are required to attend interviews with Wuhua MIMC and to rectify the relevant non-compliance; and

2. the temporary suspension of the Insurance Service Agreement entered into between Wuhua Yongke and Wuhua MIMC for a period of 61 days commencing 1 November 2025 (the "**Suspension Period**").

Save as disclosed above, Wuhua Yongke and/or Wuhua Hemodialysis Centre is not subject to other penalty. The Company takes the non-compliances seriously and will promptly implement rectification measures to fulfil the requirement under the Notice and prevent the reoccurrence of similar incidents, such rectification measures include but not limited to, full internal control review on the operation of Wuhua Hemodialysis Centre, specifically on medicine prescription procedures, and assigning additional staff to Wuhua Hemodialysis Centre to monitor operation practices and procedures so as to ensure strict compliance with applicable laws and regulations of the PRC. The Company also reviewed the operation practices and procedures in other hemodialysis centres operated by the Group and confirmed that no such similar non-compliances were identified in other centres.

During the Suspension Period, Wuhua Hemodialysis Centre will remain open and will only carry out those services not covered by Insurance Service Agreement and Wuhua Hemodialysis Centre will not carry out any hemodialysis services as such kind of services are subject to the Insurance Service Agreement. During the Suspension Period, the Group will redirect the existing hemodialysis patients of Wuhua Hemodialysis Centre to other hemodialysis treatment centres and/or hospital in the vicinity. The Company considers that as at the date of this announcement, the limited operation of Wuhua Hemodialysis Centre during the Suspension Period will not have material adverse impact on the financial position, business or daily operation of the Group.

The Company will make further announcement(s) to update the shareholders and potential investors on any significant development as and when appropriate in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board
Wanjia Group Holdings Limited
Wang Jia Jun
Chief Executive Officer and Executive Director

Hong Kong, 28 October 2025

* *For identification purpose only*

As at the date of this announcement, the Board comprises one executive Director, namely Mr. Wang Jia Jun, one non-executive Director, namely Dr. Xiao Zhixin and three independent non-executive Directors, namely Dr. Liu Yongping, Ms. Chan Wing Shan Winsome and Ms. Xu Wei.